Revolution Medicines is trading 4.23% down at $188.61 after recent insider-sale disclosures added selling pressure following its sharp regulatory-driven rally.
- Reports identified multiple Form 144 notices and a Form 4 showing Stephen Kelsey sold shares under a Rule 10b5-1 plan.
- Coverage explicitly linked the filings to the stock’s recent weakness.
- Major U.S. indexes are modestly lower, while biotechnology is rising, making sector weakness an unlikely primary explanation.